dc.creator | Tagarakis, G. I. | en |
dc.creator | Aidonidis, I. | en |
dc.creator | Daskalopoulou, S. S. | en |
dc.creator | Simopoulos, V. | en |
dc.creator | Liouras, V. | en |
dc.creator | Daskalopoulos, M. E. | en |
dc.creator | Parisis, C. | en |
dc.creator | Papageorgiou, K. | en |
dc.creator | Skoularingis, I. | en |
dc.creator | Triposkiadis, F. | en |
dc.creator | Molyvdas, P. A. | en |
dc.creator | Tsilimingas, N. B. | en |
dc.date.accessioned | 2015-11-23T10:49:21Z | |
dc.date.available | 2015-11-23T10:49:21Z | |
dc.date.issued | 2013 | |
dc.identifier | 10.2174/157016111106140128123506 | |
dc.identifier.issn | 1570-1611 | |
dc.identifier.uri | http://hdl.handle.net/11615/33531 | |
dc.description.abstract | Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery. Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF. Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different. Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions. | en |
dc.source | Current Vascular Pharmacology | en |
dc.source.uri | <Go to ISI>://WOS:000331058300017 | |
dc.subject | Ranolazine | en |
dc.subject | atrial fibrillation | en |
dc.subject | postoperative | en |
dc.subject | coronary artery bypass | en |
dc.subject | graft surgery | en |
dc.subject | prevention | en |
dc.subject | ANGIOTENSIN-CONVERTING ENZYME | en |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | en |
dc.subject | CARDIAC-SURGERY | en |
dc.subject | CLINICAL-OUTCOMES | en |
dc.subject | ANTIANGINAL AGENT | en |
dc.subject | CHRONIC ANGINA | en |
dc.subject | ARRHYTHMIAS | en |
dc.subject | MECHANISMS | en |
dc.subject | ISCHEMIA | en |
dc.subject | PERIOD | en |
dc.subject | Pharmacology & Pharmacy | en |
dc.subject | Peripheral Vascular Disease | en |
dc.title | Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery | en |
dc.type | journalArticle | en |